“The Evidence and Clinical Rationale for the Use of JAK Inhibitors in the Management of AD ”, Can Allergy Immunol Today, vol. 2, no. s11, pp. 3–11, Nov. 2022, doi: 10.58931/cait.2022.2s1148.